Pfizer’s $308m buy-in for Lyme disease vaccine
Pfizer partners with Valneva to progress Phase II-stage vaccine candidate for Lyme disease.
Archives for May 4, 2020
Immunomedics closes $459m stock offering to launch drug, scale manufacture
April saw the company add new CEO, receive approval for lead ADC drug, and launch a public offering of stock.
COVID-19 vaccine in one year ‘wishful thinking’
The likelihood of an effective vaccine being developed and scaled up in less than 12 months is unrealistic, suggests GlobalData analyst.